"What difference does it make if the 1Q12 sales are $20K or $200K."
The difference is a factor of 10. But that's irrelevant. The question is how they will get funding to build out to meet the demand that is clearly there. Note how, not if.
In 2009, about 72,500 women and 13,500 men did Sculptra. LaViv would be a far better solution for these people and their time with the Sculptra effect is now up. Will there be a market for laViv and a future for FCSC?
There's just too much wannabe or just plain nasty fake diligence here instead of any real due diligence. Btw, thanks to Monday, the average per share of our group is now far under 0.40. As I said elsewhere, by year end, we'll know the right picture. Still think FCSC will file bankruptcy?
News 
Market Data 
Discover 
AI
